Division of Roche
Latest From Piramed Ltd.
Researchers reported on new approaches to the knotty problem of triple-negative breast cancer, using genomics to identify ways of targeting the intractable disease with drugs already in the industry pipeline, at the San Antonio Breast Cancer Symposium Dec. 4-8.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Senior Management
Michael Moore, PhD, CEO
David Knowles, PhD, CSO & Head, R&D
Khatereh Ahmadi, PhD, Head, Bus. Dev.
Stephane Jallat, Fin. Dir., Co. Sec'y
- Contact Info
Phone: (44) (0)1753 285800
957 Buckingham Ave.
Berkshire, SL1 4NL
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.